Tikva Allocell

$8.0M Series A

Announced: Jul 28, 2026
Sector: Biotechnology
Investors: 1

Summary

Tikva Allocell raised USD 8 million in a Series A round to advance engineered cell therapies for solid tumors. The company plans to use the funds for regulatory preparation and clinical development. Tikva Allocell is a biotechnology company developing engineered cell therapies for solid tumors.

Investors

Kantharos Capital